Phase 1Recruiting
A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin
A Phase I, Single-center, Open-Label, Single-Arm, Fixed-Sequence Study to Evaluate the Drug-Drug Interaction of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin in Overweight/Obese Adult Chinese Subjects
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (Industry)
- Enrolment
- 111 planned
- Conditions
- Overweight Subject; Healthy Subjects
- Interventions
- Metformin; Empagliflozin; Midazolam; Valsartan; Warfarin; HDM1002
- Ages
- adults
- Registry
- NCT07331389
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to characterize the drug-drug intereaction of HDM1002 and metformin, empagliflozin, midazolam, valsartan, and warfarin in overweight/obese adult subjects. The safety and tolerability of HDM1002 with metformin, empagliflozin, midazolam, valsartan, and warfarin when given separately or together will also be evaluated
Primary outcomes
- AUC[0-∞]
- Cmax
- AUC[0-t]
History
Study completion
Primary completion
Registered
Started